FDA Import Alert Lifted, Apotex Says; Will Lipitor ANDA Approvals Be Far Behind?
Executive Summary
Apotex’s announcement that FDA is lifting an import alert on products manufactured at two Canadian facilities could be interpreted as a good sign for the near-term availability of Lipitor generics, either from first-filer Ranbaxy Laboratories Ltd. or subsequent ANDA filers.
You may also be interested in...
Apotex’s Generic Approvals Delayed By FDA Paperwork Snafu, Lawsuit Says
The agency’s “inexcusable delay” in granting final approval of Apotex’s ANDAs for Avapro and Avalide has caused the company to “fall fatally behind” in the marketplace now that 180-day exclusivity for the antihypertensive agents has expired, the manufacturer alleges.
Apotex Seeks Restitution For FDA Import Alert Before World Bank’s Arbitration Arm
Apotex claims an FDA import alert on two of its facilities caused damages in excess of $520 million; its complaint alleging U.S. government violation of NAFTA is the second it has brought before the International Centre for Settlement of Investment Disputes.
India's Race For Lipitor: More Than Five Players May Blunt Generic Gains In Post-Exclusivity Period
MUMBAI - Two years after Pfizer Inc. filed a patent infringement lawsuit against India's Dr. Reddy's Laboratories Ltd. in a bid to ward off threats to its blockbuster brand Lipitor (atorvastatin), the two companies filed a joint motion Aug. 19 to dismiss the case at the U.S. District Court of Delaware. The case was dismissed Aug. 29 but the terms and conditions of the settlement and a likely launch date for the generic versions of Dr. Reddy's product were not disclosed